Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Molecular Mining Secures $8 Million in Additional Funding

This story was updated from a previous version.

NEW YORK, May 23 – Molecular Mining, a Kingston, Ontario-based bioinformatics company, said Tuesday it had raised about $8 million in a second round of financing.

The lead investor was CDP Sofinov, a subsidiary of the Caisse de depot et placement du Quebec. Other investors included Business Development Bank of Canada; S.R. One Limited, a subsidiary of GlaxoSmithKline; Cardinal Partners; and CMDF Queen’s Scientific Breakthrough Fund.

S.R. One Limited and Cardinal Partners also participated in Molecular Mining's initial $2 million round of financing in March 1999. 

Evan Steeg, CEO of Molecular Mining, said the company would use the new resources to advance commercialization efforts for its recently launched GeneLinker software product as well as the company's collaboration and discovery services.

" There’s been a lot of industry discussion around what are the best business models for genomics and bioinformatics – is it selling tools, is it doing collaborations, is it mining your own data – we think there’s value in all three and our investors do as well, so they’ve invested in us going forward aggressively on all three," said Steeg. 

In April Molecular Mining launched its first commercial product, its GeneLinker Gold gene expression analysis software. The entry-level product uses publicly available clustering algorithms and was introduced at a list price of $5,000.

Steeg said the additional funding would speed development of the company's upcoming GeneLinker Platinum and Diamond products.

Molecular Mining also expects to "more than double" its staff and open a US office in the coming year, Steeg said.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.